AZN•benzinga•
AstraZeneca Announced Imfinzi and Tremelimumab With Chemotherapy Demonstrated Sustained Survival Benefit in Metastatic Non-small Cell Lung Cancer, Nearly Doubling the Number of Patients Alive After Three Years vs Chemotherapy
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 11, 2022 by benzinga